Gisoo Barnes

Publication Activity (10 Years)

Years Active: 2022-2024
Publications (10 Years): 6

Top Topics

Epidermal Growth Factor Receptor

Small Cell Lung Cancer

Top Venues

Cancer medicine

Future oncology (London, England)

This page only lists publications with an associated author ORCID identifier.

Publications

Yunpeng Yang, Jianji Pan, Nianyong Chen, Ye Guo, Xiaoming Huang, Yanjie Wu, Shiangjiin Leaw, Fan Bai, Yu Wang, Na Zhao, Boxiong Tang, Gisoo Barnes
Effects of tislelizumab on health-related quality of life in patients with recurrent or metastatic nasopharyngeal cancer. Head & neck (2024)
Yunpeng Yang, Jianji Pan, Nianyong Chen, Ye Guo, Xiaoming Huang, Yanjie Wu, Shiangjiin Leaw, Fan Bai, Yu Wang, Na Zhao, Boxiong Tang, Gisoo Barnes
Effects of tislelizumab on health-related quality of life in patients with recurrent or metastatic nasopharyngeal cancer. Head & neck 46 (9) (2024)
Yunpeng Yang, Jianji Pan, Nianyong Chen, Ye Guo, Xiaoming Huang, Yanjie Wu, Shiangjiin Leaw, Fan Bai, Yu Wang, Na Zhao, Boxiong Tang, Gisoo Barnes
Effects of tislelizumab on health-related quality of life in patients with recurrent or metastatic nasopharyngeal cancer. Head & neck 46 (9) (2024)
Alessandra Tedeschi, Constantine S Tam, Roger G Owen, Christian Buske, Véronique Leblond, Meletios Dimopoulos, Miriam Santero, Jorge J Castillo, Judith Trotman, Steven P Treon, Keri Yang, Boxiong Tang, Heather Allewelt, Sheel Patel, Wai Y Chan, Aileen Cohen, Shengnan Chen, Gisoo Barnes
Health-related quality of life in patients with Waldenström macroglobulinemia: results from the ASPEN trial. Future oncology (London, England) (2024)
Dingzhi Huang, Cai-Cun Zhou, Gisoo Barnes, Yiyuan Ma, Songzi Li, Lin Zhan, Boxiong Tang
The effects of tislelizumab treatment on the health-related quality of life of patients with advanced non-small cell lung cancer. Cancer medicine (2023)
Rajwanth R Veluswamy, Fred R Hirsch, Emanuela Taioli, Juan Wisnivesky, Ross Strauss, Douglas Harrough, Boxiong Tang, Gisoo Barnes
Real-World longitudinal practice patterns in the use of PD-1 and PD-L1 inhibitors as First-Line therapy in patients with Non-Small cell lung cancer in the United States. Cancer medicine 11 (22) (2022)